Phathom Pharmaceuticals Earnings Call Signals VOQUEZNA Momentum

Phathom Pharmaceuticals (PHAT) reported Q3 revenue of $84.7M, up 71% YoY, with operating profit of $5.8M. VOQUEZNA prescriptions exceeded 2M, with 380K in Q3. Management highlighted strong payer coverage, cash position, and profitability outlook, but noted margin pressure and exclusivity litigation risks.

Original reporting
Published Nov 15, 2026, 12:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 9:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PHAT
Neutral
medium confidence
Mentioned
$PHAT
Relevance
4/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$PHATNeutralLow
01

Why it matters

The call provides no new quantitative data beyond the prior release; investors are unlikely to adjust positions.

02

Market read

Recap of already‑published earnings; limited trading relevance.

03

What to watch

Potential litigation risk and margin pressure could become material if not resolved.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Phathom Pharmaceuticals held its Q3 earnings call, reiterating strong revenue growth, profitability, and 2026 guidance.

Company-level read

Ticker impact

$PHATNeutralMedium confidence
Context

Recap of Q3 earnings call with revenue, profit, cash flow and reaffirmed 2026 guidance already disclosed earlier.

Expected impact

likely limited impact as information already priced

Evidence & confidence

The article repeats numbers and guidance that were public 17 days ago; no new catalyst.

Market effects

None beyond reaffirming strength of the GERD drug market.

No regional effect noted.

Minimal.

Counterpoint

Even though the call is positive, the lack of new data suggests the stock may have already run up on the original release.

Key entities

  • Phathom Pharmaceuticals

    Developer of VOQUEZNA, a GERD treatment.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.